AzTrials
AzTrials

Neonatal HypoglycemiaNCT07133906

Accuracy of Interstitial Continuous Glucose Sensors in Neonates

An observational study of Neonatal Hypoglycemia and Gestational Diabetes, run by Women and Infants Hospital of Rhode Island.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Low blood sugar in newborns is common and if prolonged or untreated may place them at increased risk for later learning and behavior challenges. Currently, we measure newborn glucose with at least four painful heel sticks, missing one in four episodes of low blood sugar. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
What is being tested?
Continuous glucose monitoring and Cerebral near-infrared spectroscopy
Type of treatment
Medical device
How many people
114 participants
Where
No sites listed yet
Study dates
Sep 2025to Jun 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: Antenatal floor, labor and delivery unit (L\&D), neonatal intensive care unit (NICU), mother baby unit (MBU), and obstetrics and diabetes clinics at Women and Infants Hospital

Who may be able to join

  • women aged 18 years or older
  • speaks English, Spanish, Portuguese, or Haitian Creole
  • pregnant >24 weeks gestation with singleton pregnancy

Who cannot join

  • known concomitant maternal or fetal condition which, in the opinion of the investigator, could present a risk to the safety or welfare of the subject or study staff
  • plans to deliver at a hospital other than Women and Infants Hospital of Rhode Island

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Sarbattama Sen, MD contact

401-274-1122

ssen@carene.org

Isabella Lawandy contact

401-274-1100

ilawandy@wihri.org

About this study

Low blood sugar in newborns is common and if prolonged or untreated may place them at increased risk for later learning and behavior challenges. Currently, we measure newborn glucose with at least four painful heel sticks, missing one in four episodes of low blood sugar. The goal of this observational study is to develop a less invasive approach to glucose monitoring, developed for newborns, that provides more frequent glucose measurements. We will also measure how a pregnant woman's health impacts newborn glucose, and how newborn glucose is linked to brain oxygen saturation and development.

Read the detailed description

Glycemic control in newborns remains a major challenge for neonatal care. One third of U.S. infants are screened for neonatal hypoglycemia (NH) with repeated, painful heel sticks, most commonly based on dichotomous maternal diabetes determination or newborn size. Yet, less than 50% of these infants subsequently develop and are treated for hypoglycemia. If treatment is needed, it is based on "operational thresholds" that do not account for the actual effect of glycemia on brain metabolism, nor for its long-term consequences, and potentially expose infants to unnecessary treatment that may further amplify harm. Thus, both screening and treatment for NH lack precision and are not driven by physiology or outcome.

Improving NH risk stratification requires maternal metabolic and neonatal glycemic characterization in a cohort that includes dyads considered at-risk, with comparison to not-at-risk controls. Establishing "functional thresholds" for glycemic treatment requires evaluation of reliable bedside measurable proxies of brain metabolic "health" during the neonatal period. Further, these need to contextualised within the longitudinal trajectory of the domains known to be impacted by NH, namely executive and visual motor function. These critical domains have not been investigated together in one pre-birth, longitudinal cohort, and this knowledge gap has limited advancements in NH care.

  • The primary objective of this observational study is to characterize the Abbott FreeStyle Libre 3 Pro continuous glucose monitoring system performance with respect to point of care whole blood reference in neonates.
  • A secondary objective is to determine maternal and neonatal predictors of NH and child neurodevelopment.
  • A secondary objective is to identify glycemic and cerebral saturation thresholds of exposure linked to adverse neurodevelopment.

Study Design

  • Non-randomized, single arm, single-center, prospective, observational study

Study Procedures Visit 1 (V1) t: 30-36 weeks' gestation

Procedures:

  • Complete the following electronic surveys and questionnaires: Demographics, Holmes-Rahe Life Stress Inventory, Infant Feeding Intentions Questionnaire, and the Fat/Sugar/Fruit/Vegetables Screener.
  • Participants will be provided blood self-collection kits and asked to provide fasting blood samples at 35-37 weeks gestation, to be archived for later measurement of metabolic markers.

Visit 2 (V2): post-delivery in hospital

Procedures:

  • All infants will have blinded FreeStyle Libre 3 Pro Continuous Glucose Monitors placed on the lateral thigh by the PI or trained staff which will be continued to hospital discharge or for 10 days, depending which occurs first.
  • Near Infrared Spectroscopy (NIRS) probe will be placed on the forehead of the infant, connected to a monitor that will be blinded (covered) to the parents and clinical team.
  • Infants will have additional research blood drawn (50 uL) by heel stick or venipuncture (based on clinical method of blood collection) at least twice.
  • Any extra blood available will be used to measure ketones and lactate using a hand-held meter.
  • Every effort will be made to align research blood draws with clinical draws, however, if this is not possible, enrolled infants will have an additional 1-2 heel sticks daily for research purposes.
  • Infant body composition will be measured using air displacement plethysmography (PeaPod TM) and bioimpedance assay within 72 hours of life.
  • Infant weight and length will be measured.
  • The Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) will be administered by an NNNS trained and certified staff.
  • Additional clinical data will be extracted from the both the maternal and infant medical record.

Visit 3 (V3): 6 months of life (between 5 and 7 months of age) - Parent will complete the following electronic questionnaires: 6-Month Ages and Stages Questionnaire, Breastfeeding Status Questionnaire, and the Infant Feeding Practices Survey (6 Months).

Visit 4 (V4): 1 year of life (between 11 and 13 months of age)

  • Procedure: Parent will complete the following electronic questionnaires: Breastfeeding Status Questionnaire, Infant Feeding Practices Survey (12 Months), 1-Year Ages and Stages Questionnaire, Child Health Questionnaire, and the Brief Infant Toddler Social and Emotional Assessment (BITSEA).

Additional clinical data will be abstracted from the medical record of the mother and infant after discharge. Study staff will complete chart reviews for key pregnancy health variables outlined in the "Medical Record Abstraction Form" and enter into study database.

Cord blood will be collected and archived for a subset of subjects.

Being tested
Continuous glucose monitoring, Cerebral near-infrared spectroscopy
Medical subject headings
Diabetes, Gestational

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Continuous glucose monitoringDevice

    A blinded Abbott Freestyle Libre 3 Pro will be placed on the newborn

  • Cerebral near-infrared spectroscopyDevice

    Blinded cerebral near infrared spectroscopy will be assessed

Study groups in NCT07133906
Study groupRoleWhat they receive
Pregnant women >24 weeks gestation and their infantsPregnant women >24 weeks gestation; infants of pregnant women >24 weeks gestation, including 11 infants of women with gestational diabetes, 11 infants of women with type II diabetes, 11 infants of women with type I diabetes, 6 small-for-gestational age (SGA) infants, 6 large-for-gestational age (LGA) infants, and 12 control infants who are not considered at-risk for hypoglycemia.
Receives: Device: Continuous glucose monitoring; Device: Cerebral near-infrared spectroscopy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Point Accuracy: System agreement analysis

    Number and percent of glucose monitoring (GM) sensor results within the intervals +/- 20% of glucose reference throughout the system measuring range

    Measured: From time of birth to discharge, an average of 3 days

Secondary outcomes (3)
  1. Episodes of neonatal hypoglycemia (NH) by risk factors

    Count of neonatal hypoglycemia (NH) episodes in infants born with various maternal and neonatal risk factors (maternal diabetes, maternal gestational glucose intolerance, maternal obesity, fetal growth abnormalities, maternal beta blockers, and preterm delivery) or no risk factors.

    Measured: Between birth to 72 hours after birth

  2. NNNS scores

    NNNS subscale score quartiles

    Measured: From time of birth to 72 hours after birth, at an average of 48 hours of age

  3. ASQ scores

    Ages and Stages (ASQ) scores

    Measured: 6 months and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Aug 2025
  2. Study startSep 2025 (estimated)
  3. Primary completionDec 2026 (estimated)
  4. Study completionJun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
114 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07133906
Sponsor's protocol ID
2177993
Status last verified
Aug 2025
First submitted
22 Jul 2025
Last updated
21 Aug 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Neonatal Hypoglycemia and Gestational Diabetes, run by Women and Infants Hospital of Rhode Island.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 21 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sarbattama Sen, MD (401-274-1122, ssen@carene.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Point Accuracy: System agreement analysis (time frame: From time of birth to discharge, an average of 3 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in